Leadership in cardiac surgery by Rao, Christopher et al.
www.elsevier.com/locate/ejcts
cic Surgery 39 (2011) 905—911European Journal of Cardio-thoraReview
Leadership in cardiac surgery
Christopher Rao a, Vanash Patel a, Michael Ibrahim b, Kamran Ahmed a, Kathie A. Wong a,
Ara Darzi a, Ludwig K. von Segesser c, Thanos Athanasiou a,b,*
aDepartment of Biosurgery and Surgical Technology, Imperial College, London, UK
bDepartment of Cardiothoracic Surgery, National Heart and Lung Institute, Imperial College, London, UK
cDepartment of Cardiovascular Surgery, University Hospital CHUV, Lausanne, Switzerland
Received 6 June 2010; received in revised form 10 August 2010; accepted 16 August 2010; Available online 29 September 2010SummaryDespite the efficacy of cardiac surgery, less invasive interventions withmore uncertain long-term outcomes are increasingly challenging surgery
as first-line treatment for several congenital, degenerative and ischemic cardiac diseases. The specialty must evolve if it is to ensure its future
relevance. More importantly, it must evolve to ensure that future patients have access to treatments with proven long-term effectiveness. This
cannot be achieved without dynamic leadership; however, our contention is that this is not enough. The demands of a modern surgical career and
the importance of the task at hand are such that the serendipitous emergence of traditional charismatic leadership cannot be relied upon to
deliver necessary change. We advocate systematic analysis and strategic leadership at a local, national and international level in four key areas:
Clinical Care, Research, Education and Training, and Stakeholder Engagement. While we anticipate that exceptional individuals will continue to
shape the future of our specialty, the creation of robust structures to deliver collective leadership in these key areas is of paramount importance.
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It should be a relief to all physicians that medicine
evolves, practice changes and obsolete specialties die. It is
incumbent on us to ensure that this is driven by improve-
ments in patient care.
Cardiac surgery tentatively stands on a precipice — its
future growth uncertain. It has always been a challenging
specialty, driven by strong, pioneering leaders [1]. Failure of
leadership has always had obvious, devastating consequences
[2]; however, the need for reconfiguration of leadership is now
mandatory. The long-term efficacy of cardiac surgery such as
valve implantation [3] and revascularization is proven [4—7];
however, many physicians and patients consider the perio-
perative morbidity and mortality to be unacceptably high,
despite favorable comparisons with other major surgeries [8].
This has resulted in the development of several technologies —
most significantly, percutaneous techniques [9,10]. While
these techniques may have uncertain long-term efficacy, they
clearly reduce procedural morbidity and mortality [11,12].* Corresponding author. Address: Department of Biosurgery and Surgical
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percutaneous interventions, whereas the number of bypass
operations has remained stable or declined [13,14].
The specialty now has limited ability to respond to
changing circumstances because of the historic focus of
pioneering surgeons on personal development at the expense
of training, and the growing separation of cardiac surgery
from the diagnostic process, in contrast to other specialties
such as ophthalmology or urology which continue to control
the entire value chain.
The leadership cardiac surgeons demonstrate in key areas
will determine whether they maintain a central role in the
management of ischemic and degenerative cardiovascular
pathology or whether they become practitioners of a revered
yet essentially peripheral surgical specialty. More impor-
tantly, it will determine whether future patients will have
access to interventions with proven long-term efficacy [5]. In
this article, we discuss why the specialty must evolve and
how a new generation of leaders can facilitate change in four
key areas (Fig. 1).
1.1. Clinical leadership
The primary driver for cardiac surgery to adapt is the need
to improve patient outcomes [8]; consequently, clinicalSurgery. Published by Elsevier B.V. All rights reserved.
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Fig. 1. Cardiac leadership.
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Fig. 2. The Iceberg model: a framework for viewing quality improvement tools
and methods [18].leadership is critical. Societal trends such as increasing
population age have resulted in older patients with greater
co-morbidity undergoing cardiac surgery [15]. This increases
the pressure to improve operative outcomes as it is less likely
that these patients will benefit from the long-term benefits
associated with cardiac surgery. This is challenging as the co-
morbidities of these patient groups also increase the
likelihood of poor operative outcomes [16].
To be a ‘good surgeon’ is an important prerequisite of
being an effective clinical leader. It is not however the only
prerequisite and good surgeons are not necessarily effective
clinical leaders. Clinical leadership in cardiac surgery has two
important elements:1. Quality management: Although the operating surgeon has
traditionally had responsibility for patient outcomes, the
quality of patient care is too important to rest with one
individual. Healthcare delivery must be quality-driven
with organizational structures to ensure continuous
incremental quality improvement. Performance must
be continuously audited not only to ensure transparency
but also because there is emerging evidence that this is an
important quality improvement tool [17]. While ultimate
responsibility for patient care may continue to rest with
the surgeon, every member of the team should feel
empowered to participate in quality improvement. A
culture of rationalizing current practice and early
adoption of interventions with proven efficacy should
be encouraged. Although quality management models
have existed since the 1920s to facilitate the develop-
ment of a quality-driven culture within commercial
organizations, their application in healthcare, where
quality management has traditionally been the responsi-
bility of individual clinicians, is relatively recent.
Strategic change requires underlying theories, para-
digms and assumptions to be reviewed. This will
invariably change core systems and processes, which will
in turn affect everyday tools, methods and procedures.
Consequently, quality management models can be
categorized as relating to (a) everyday tools, methods,and procedures; (b) core systems and processes or (c)
underlying theories, paradigms and assumptions (Fig. 2).
Quality management models have different strengths and
weaknesses, although many were not designed to be
applied in healthcare. It is therefore important that these
models should be tailored to meet the needs of individual
organizations and teams [18].2. Disruptive innovation is a term used in business and
technology to describe innovations that improve a
product or service in ways that the market does not
expect in contrast to continuous, sustaining innovation
which results in incremental improvement [19,20].
Improvements in long-term outcomes following cardiac
surgery have reached a plateau where incremental gains
are at the expense of progressively increasing resources.
Similarly, while quality improvement frameworks are
important, the extent to which operative morbidity and
mortality can be improved within the constraints of
current technology and practice is limited. Consequently,
improvement in patient outcomes can only be sustained
with disruptive innovation. Novel technology such as
tissue engineering, minimal access instrumentation, less
invasive perfusion and mechanical support systems need
to be core elements of future cardiothoracic practice.
The challenge is to deliver tangible benefits to patient
care quickly and safely. The pioneers of cardiac surgery
innovated in an era when alternative treatments were
few, if any [1]. Any success was complete success. As
ischemic and degenerative heart disease is now managed
with relative success, any failure is now complete failure.
This is the reason why academic leadership is an essential
adjuvant to clinical leadership in modern cardiothoracic
surgery.
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As academic leadership becomes more important to the
future of cardiac surgery its practice becomes more difficult
[21]. The science and technology that underpinned any
aspect of cardiac surgery were once readily accessible to the
well-informed surgeon. The sophistication of cardiac
surgery has increased exponentially and the frontier of
scientific and technological understanding is now far from
clinical practice. Complex engineering and technology will
facilitate the next generation of operating platforms. Tissue
engineering, stem cell biology, advanced imaging techni-
ques and individualized pharmacotherapy may play an
important role in the future of cardiac surgery. This has
numerous implications for the future leaders of academic
cardiac surgery, including the following:1. Modern research must be multi-disciplinary, and any
future leader in cardiac surgery must have strong
interpersonal skills and the ability to build cohesive
multi-disciplinary teams.2. It is crucial that cardiac surgeons have a robust scientific
background in the technologies that will define the future
of cardiac surgery. It is no longer acceptable for cardiac
surgeons to do research for the sake of doing research, for
career progression or to tick a box on the curriculum
vitae. The future of the specialty is dependent on cardiac
surgeons looking to the long-term future of the specialty
when completing their research and being viewed as
credible physician-scientists by potential academic col-
laborators.3. It is important that structures are created at a
departmental, local, national, and international level
to facilitate rapid technology transfer from the laboratory
to the clinic with reciprocal transfer of information back
to the laboratory to inform future innovation. This will
require investment, the creation and strengthening of
structures and the involvement of cardiac surgeons at
every stage.4. The dynamic nature of cardiovascular technology makes
traditional methods for evaluating novel practice prob-
lematic. This has historically resulted in some areas of
practice developing without being underpinned by a
strong evidence base with potentially detrimental con-
sequences for patients. Conversely, many patients are
denied potentially effective treatments as surgeons are
justifiably reluctant to apply technology when there is
little evidence supporting its effectiveness. Consequent-
ly, it is incumbent on surgical academics to develop a
pragmatic framework with which to evaluate new
technology. This will require a multi-center, regional or
even nationally coordinated permanent clinical trial
networks to ensure that novel technology can be quickly
and robustly evaluated. Clinical trials must be integrated
with registries to ensure their applicability to clinical
practice. A framework must be developed to provide
clinical guidance in conditions of uncertainty or imperfect
information. This will require the development and
popularization of novel methodological tools.5. Selection of the optimum strategy in clinical practice
often requires multiple outcomes to be considered. As theevidence is often complicated or apparently contradicto-
ry [22,23], academic cardiac surgeons must continue to
be actively engaged not only with other academics, but
also with the patients and the wider medical community
to ensure that all relevant evidence is considered [24,25].6. Finally, surgeons of all levels of seniority should be
encouraged to engage in research and technology transfer
that will have an impact on patient care. This presents
two challenges: first, if surgeons are to be encouraged to
engage in research they must be incentivized to engage in
research that is useful and scientifically robust. Second,
for surgeons to be effective academics, academic training
must be integrated with surgical training. While this may
be challenging, it is imperative both to ensure that
individual surgeons are equipped to engage in high-impact
research and to ensure that the specialty maintains its
strategic importance.
1.3. Education and training
Despite some interest in anastomotic devices, anastomo-
tic techniques have remained largely unchanged since the
Carrel techniques were first described in 1902 [26]. By
contrast, the advent of minimally invasive operating plat-
forms and off-pump coronary artery bypass grafting has made
the operating environment significantly more challenging as
cardiac surgeons are forced to operate through smaller
incisions on moving targets, often using tools that are not
intuitive [27]. Other aspects of cardiac surgery, such as valve
surgery, are also becoming technically more challenging as
preservation and repair is increasingly preferred to replace-
ment [28].
Training cardiac surgeons to perform increasingly
demanding procedures is problematic, especially as out-
comes are now strictly audited and the profession and
general public are justifiably less tolerant and more
conscious of medical error [29]. While not the primary
cause, changes to career structure and employment law in
some countries may also augment this problem [30].
There is no easy solution to the problem of training
tomorrow’s cardiac surgeons; however, several central
paradigms of surgical training must change. Training needs
to be structured while focusing on competencies and not the
time spent on them. The concept of a defined training that
formally ends in final accreditation is outdated. It does not
reflect that accreditation should be based on competency
and that a surgeon who is safe and competent to perform
some aspects of cardiac surgerymay not also be competent to
perform all other aspects of the specialty. It suggests that
personal development and training slows down, or even
arrests, after completion of training. The pace of innovation
that is both likely and necessary in cardiac surgery will force
training to continue throughout a surgeon’s career [31]. The
reluctance of senior surgeons to learn new techniques cannot
be allowed to block innovative practice that will improve
care [32]. Finally, the concept of a formal training period
resulting in accreditation does not reflect that individuals
will acquire the multi-faceted skill-set needed for a career in
modern cardiac surgery in different sequences and at
different rates.
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Fig. 3. The healthcare environment.
Fig. 4. The 2003 global cardiovascular device market, $ billions (%) [33].Strong leadership is important to ensure that trainers,
trainees, relevant professional colleagues and healthcare
providers are involved in designing and modifying training
programs to ensure that they fulfill both current and future
requirements of cardiac surgeons. Robust mechanisms must
ensure that training is designed with the ultimate goal of
patient benefit in mind. Traditional surgical apprenticeship
will need to be supplemented by high-fidelity simulation and
wet-lab experience for surgeons of all seniority. Continuous,
iterative change to training programsmay bemore successful
than radical restructuring and leaders must ensure that a
dynamic framework exists in which change can occur and be
evaluated.
1.4. Stakeholder engagement
The traditional model of clinical care consists of the
clinician ‘provider’ delivering care to patient or ‘consumer’
of healthcare. In reality, this is far more complicated; usually
a third-party ‘payer’, such as an insurance company or
government, pays for the cost of healthcare. The modern
surgeon also usually represents the end of a complex ‘value-
chain’ in which medical device companies and other
commercial organizations are important partners [33]. The
involvement of several stakeholders significantly complicates
the climate in which care is delivered and successful leaders
in cardiac surgery must consider the role of all stakeholders.
1.4.1. Government and insurance companies
Aging populations in the developed world have resulted in
greater demand for health and social care, relative to
taxation revenues and insurance contributions. As patient’s
expectations of healthcare and the cost of delivering modern
healthcare are also increasing, third-party payers increas-
ingly seek to rationalize spending on healthcare [34].
Similarly, spending on clinical research [35—37] and educa-
tion [38] is being critically appraised and rationalized. A
successful head of department must be financially astute to
ensure that core clinical, teaching and research activities are
adequately funded [39]. They must also be familiar with the
complex conceptual framework and vocabulary that is used
to justify the cost-effectiveness of clinical interventions and
increasing research [40].
1.4.2. Industry
The involvement of commercial organizations such as
manufacturers of medical device companies in the value
chain deserves special consideration. Unlike other markets,
the ‘consumer’ or patient does not choose the product. This
is done by the ‘providers’ of care. Often neither the
‘provider’ nor the ‘consumer’ pays for the product; instead,
a third-party ‘payer’ finances purchasing of the product. The
‘payer’ often recovers costs from ‘consumers’ only indirectly
through taxation or insurance premiums and, as a result,
individual patients will largely be unaware about the cost of
their care. This has resulted in unique market dynamics in
which the cost of a device is unrelated to the demand for it
and the demand is, to an extent, determined by the
manufacturer. For example, devices can be improved
incrementally, unlike pharmaceuticals, in order to justify
the cost demanded by manufacturers. Continuous incre-mental improvement also makes performing robust clinical
trials difficult. Consequently, it is almost impossible for
‘payers’ to control costs without the cooperation of
‘providers’ who have specialist knowledge of device func-
tion. Often neither ‘providers’ nor ‘consumers’ pay for
devices; consequently, there is little incentive to seek value
for money and as a significant increase in the cost of a device
may represent only a marginal increase in cost compared to
the cost of the operating theatre staff, other consumables,
perioperative care and long-term follow-up, there may not
even be much incentive for ‘payers’ to seek value for money
[33]. As the ‘provider’ lies in the center of this complicated
‘web’ of healthcare finance, surgical leaders have both
additional responsibility and opportunities (Fig. 3).
In 2003 the global cardiovascular devices market was
worth approximately $16.2 billion annually. Surgical devices
accounted for only 15% ($2.5 billion) of this market and had a
growth rate of 17%. Interventional cardiology accounted for a
third of the market ($5.4 billion) and had a growth rate of
over 35%. Coronary stents alone are worth more than all
surgical cardiovascular devices combined ($3.4 billion) with a
growth rate of 50% (Fig. 4) [33]. As the medical device sector[()TD$FIG]
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clinical practice and uniquely drives demand for their own
products, surgeons must engage with this sector or device
manufactures will go where there is a market for their
products — to interventional cardiology. If cardiac surgery
does not continue to employ innovative technology it will
become extinct as will the paradigm of revascularization
using anatomical bypass whichmay continue to be relevant in
certain population subgroups.
The involvement of industry in medical research, although
widespread and arguably essential [41], has traditionally
been viewed with suspicion because of potential conflicts of
interest [42]. The need to obtain research funding of any kind
may, however, be associated with unethical behavior [43,44].
Industry-funded research is cited more, suggesting it may be
of a higher quality [45]. Furthermore, there is evidence to
suggest that industry funding of research accelerates the
translation of technology into patient benefit [46]. As cardiac
surgery becomes increasingly dependent on expensive
science, technology and intellectual property, industry
involvement may be critical. The role of commercial
organizations in study design, analysis and the decision to
publish must be explicit and regulated. Care must be taken to
ensure that patient benefit, and not commercial interest, is
driving healthcare innovation [8]. If this is achieved in a
robust, pragmatic and transparent manner not only would
this be superior to many contemporary models for industry
involvement but may have benefits for patients, healthcare
providers, academics and surgeons.
Similarly, the role of commercial organizations in educa-
tion and training must also be considered [47]. Training
cardiac surgeons requires investment of considerable time
and resources. As the future is uncertain, involvement of
industry stakeholders in training may help to ensure the skills
of future cardiac surgeons meet the demands of future
technology. To involve commercial organizations in training
programs in a meaningful fashion without compromising their
integrity and focus on the quality of patient care is a
substantial but necessary challenge for the leaders of cardiac
surgery.
1.4.3. Patients and colleagues
Patients are often neglected key stakeholders. Ultimately,
the most pressing driver for cardiac surgery to evolve is the
general dissatisfaction thatmany patients and physicians feel
with the operative morbidity and mortality associated with
cardiac surgery. The leadership of cardiac surgeons must
respond to the concern of patients with clinical, academic
and educational innovation. They must also work with
medical colleagues and patients to assist patients in making
complex trade-offs between long-term benefits and short-
term disutility that is inherent in many types of surgery. This
may require consent procedures and the methods by which
we articulate and explain risk to patients to be reviewed, in
order to ensure that all stakeholders are fully engaged. For
example, there is evidence to suggest that patients perceive
the long-term risks associated with percutaneous interven-
tions to be lower than physicians [48,49]. While differential
perception of procedural risk by patients and physicians is not
confined to cardiovascular medicine [50], this must be
addressed. Where current best practice is not beingimplemented [51,52] the reasons should be explored openly,
without blame and recrimination. This may require involve-
ment of the wider profession and multi-disciplinary team
actions. In Europe this now has added significance, as
following the accession of the European Convention on
Human Rights into the Law of Member States, informed
consent is no longer a matter of professional good practice
but has a firm legal basis [52]. Finally, cardiac surgeons should
investigate novel diagnostic strategies that may facilitate
more direct patient engagement [53,54].2. Leadership structures
Whether it is possible for one individual to be a clinically
active cardiac surgeon, a good teacher and an excellent
researcher while fulfilling other responsibilities, is question-
able [55]. The demands placed on leaders can be so onerous
as to discourage long-term involvement of the most talented
[21]. While historically there have been many models of
leadership, the importance of distributive leadership is
increasingly recognized [56]. Consequently, not only are
effective leaders required but also effective leadership
structures, aligned with organizational strategic goals
[18,57]. Leadership structures must provide the authority
and framework for decision-making to be delegated and
responsibility to be shared. Sufficient information, training
and logistic support must be provided to facilitate good
decision-making. Leadership structures must achieve the
difficult balance of promoting engagement while still
permitting strategic decisions to be made quickly and
efficiently. Leadership in the key areas that we have
identified is needed nationally and internationally; however,
the foundation for this is the development of strong local
leadership structures. Leadership structures must work even
when our leaders are not exceptional, while simultaneously
allowing exceptional individuals to flourish and be supported.
Ultimately, patient interest must come first and every
cardiac unit must have a culture of excellence through
collective clinical leadership and accountability, regardless
of level or role. Clinical excellence alone however is not
enough, and cardiac surgeons who are not only good
clinicians but will also show leadership in other areas in
which they excel must be actively recruited. Examples of
such professionals can be the recruitment of a talented
teacher to head the department’s training commitments or
an academic surgeon to collaborate with scientific collea-
gues, formulate and define research strategy and supervise
research students. There is considerable interest in devel-
oping leadership in clinical trainees [58,59]; how to achieve
this for surgeons and surgical trainees needs to be better
understood and characterized [60].
The concept of the rounded surgical leader, embedded
within effective leadership structures in which leadership is
distributed, may contrast markedly from the traditional
notion of a charismatic leader [61]. This is deliberate. First,
our concept of surgical leadership facilitates structured
development of individual and institutional leadership
capabilities. Secondly, while the charismatic surgical leaders
undoubtedly have unparalleled capacity to innovate and
improve services, they can equally often be a conservative
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patient care [32,62].
3. Conclusion
Our specialty needs to evolve to avoid being sidelined. It is
our duty to ensure that this does not occur. Future patients
must have choice and access to the best long-term
interventions. Furthermore, the development of cardiovas-
cular science is enhanced by having a spectrum of biological
and clinical perspectives.
The need for innovation and leadership in cardiac surgery
is considerable but should not be daunting. If we act now
these goals are achievable. In our opinion, cardiac surgery
has a tangible and promising future. Pioneering cardiac
surgeons neglected team development in order to develop
individual excellence. If we focus on leadership structures
rather than individual leaders, on incremental evolution from
the local to the international level and on developing a
culture of innovation and investment, the mistakes of the
past can be avoided and the challenges of the future can be
addressed.
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